Car-Nk Cells Targeting Nkg2D Ligands
Safety and Efficacy
Hangzhou Cheetah Cell Therapeutics Co., LtdCell therapyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Safety and Efficacy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tucidinostat Sun Yat-sen University | Phase 2 | BB |
L-Dep Sun Yat-sen University | Phase 2 | CCC |
Azacitidine Sun Yat-sen University | Phase 2 | CCC |
Tisagenlecleucel The First Affiliated Hospital of Soochow University | Phase 1/2 | CCC |
Jwcar129 The First Affiliated Hospital of Soochow University | Phase 1 | CC |
Clozapine Ruijin Hospital | Early Phase 1 | C |
Same molecule, other indications
Car-Nk Cells Targeting Nkg2D Ligands is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →